News & Updates
Filter by Specialty:
Small wins for amlitelimab in STREAM-AD
The experimental drug amlitelimab has scored positive outcomes in the double-blind, placebo-controlled phase IIb STREAM-AD study evaluating it as a treatment for moderate-to-severe atopic dermatitis (AD).
Small wins for amlitelimab in STREAM-AD
23 Oct 2023
Adult ADHD spells increased dementia risk
Adults with attention-deficit/hyperactivity disorder (ADHD) face a nearly threefold higher risk of dementia compared with those who do not have the neurodevelopmental condition, according to a study.
Adult ADHD spells increased dementia risk
22 Oct 2023
Amino acid neurotransmitters predict death, disability after ischaemic stroke
Among patients who have had a stroke, those with increased glutamic acid, aspartic acid, and gamma-aminobutyric acid and decreased glycine in plasma are more susceptible to adverse outcomes, such as death or major disability, reveals a China study.
Amino acid neurotransmitters predict death, disability after ischaemic stroke
22 Oct 2023
Do alpha-1 receptor blockers help prevent COVID-19 hospitalization?
Frequent use of alpha-1 receptor blockers is neither harmful nor protective against the risk of uncomplicated or severe COVID-19 hospitalization, a study has shown.
Do alpha-1 receptor blockers help prevent COVID-19 hospitalization?
22 Oct 2023
Nonsteroidal cream brings early relief in atopic dermatitis itch
In children and adults with moderate-to-severe atopic dermatitis, applying tapinarof cream 1% helps reduce itch within 24 hours, according to the results of the phase III trials ADORING 1 and 2.